Biokinetic analysis of tissue boron (10B) concentrations of glioma patients treated with BNCT in Finland

A total of 98 patients with glioma were treated with BPA-F-mediated boron neutron capture therapy (BNCT) in Finland from 1999 to 2011. Thirty-nine (40%) had undergone surgery for newly diagnosed glioblastoma and 59 (60%) had malignant glioma recurrence after surgery. In this study we applied a close...

Full description

Saved in:
Bibliographic Details
Published in:Applied radiation and isotopes 2015-12, Vol.106, p.189-194
Main Authors: Koivunoro, H., Hippeläinen, E., Auterinen, I., Kankaanranta, L., Kulvik, M., Laakso, J., Seppälä, T., Savolainen, S., Joensuu, H.
Format: Article
Language:English
Subjects:
10B biodistribution
BNCT
Boron - pharmacokinetics
Boron Neutron Capture Therapy
BPA
Brain Neoplasms - radiotherapy
Dose calculation
Finland
Glioblastoma - radiotherapy
Glioma
Humans
PET
Radiotherapy Dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A total of 98 patients with glioma were treated with BPA-F-mediated boron neutron capture therapy (BNCT) in Finland from 1999 to 2011. Thirty-nine (40%) had undergone surgery for newly diagnosed glioblastoma and 59 (60%) had malignant glioma recurrence after surgery. In this study we applied a closed 3-compartment model based on dynamic 18F-BPA-PET studies to estimate the BPA-F concentrations in the tumor and the normal brain with time. Altogether 22 patients with recurrent glioma, treated within the context of a clinical trial, were evaluated using their individual measured whole blood 10B concentrations as an input to the model. The delivered radiation doses to tumor and the normal brain were recalculated based on the modeled 10B concentrations in the tissues during neutron irradiation. The model predicts from −7% to +29% (average, +11%) change in the average tumor doses as compared with the previously estimated doses, and from 17% to 61% (average, 36%) higher average normal brain doses than previously estimated due to the non-constant tumor-to-blood concentration ratios and considerably higher estimated 10B concentrations in the brain at the time of neutron irradiation. •Previously no correlation between the radiation dose and survival was found in a clinical BNCT trial on recurrent GBM.•In this study a kinetic model based on 18F-BPA-PET studies was used to predict the behavior of BPA in the tissues.•Model predicts +11% and 36% higher average tumor and normal brain doses, respectively.
ISSN:0969-8043
1872-9800
DOI:10.1016/j.apradiso.2015.08.014